ロード中...

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer

The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. There has been some success in therapies targeting AR signaling which have been shown to extend survival in men with castration-resistant prostate cancer (CRPC). However, durable respon...

詳細記述

保存先:
書誌詳細
出版年:Cancer Biol Ther
主要な著者: Lochrin, Sarah E, Price, Douglas K, Figg, William D
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622075/
https://ncbi.nlm.nih.gov/pubmed/25535892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.962297
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!